Polynovo (ASX:PNV) Under Spotlights as Investors Assess Record Revenue and Cash Flow Progress

Aditi Sarkar

20 August 2026 06:42 PM AEST

Polynovo (ASX:PNV) Under Spotlights as Investors Assess Record Revenue and Cash Flow Progress

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Polynovo (ASX:PNV) closed at AUD 1.11, up 6.73% on 20 August 2026.
The company develops advanced wound care products using its NovoSorb biodegradable polymer technology.
FY26 trading update highlighted Revenue of AUD 150.0 million, up 16.1% compared with FY25.
Investors continue to monitor US commercial growth, Manufacturing expansion, product launches and reimbursement conditions.

Polynovo Limited (ASX:PNV) shares closed at AUD 1.11, up 6.73% on 20 August 2026. The movement reflects a stronger Trading session as investors continue to assess the company’s advanced wound care technology platform, global sales growth and commercial expansion strategy.

Daily share price movements can reflect changes in investor sentiment, trading activity, valuation expectations and broader market conditions. However, a single-session movement does not necessarily indicate a change in the company’s underlying fundamentals, financial position or long-term operating outlook.

Polynovo is a medical technology company focused on transforming the management of complex wounds through its NovoSorb biodegradable polymer technology. The company develops synthetic wound care products designed for applications including burns, trauma wounds and other complex wound indications.

The broader Australian market closed higher on the day. The S&P/ASX 200 (ASX:XJO) closed at 9,083.80 points, up 0.33% today, while the S&P/ASX 300 (ASX:XKO) closed at 9,019.90 points, up 0.37% today. Within the healthcare sector, the S&P/ASX 200 Health Care (ASX:XHJ) closed at 32,044.30 points, up 1.39% today.

Advanced wound care technology platform

Polynovo operates within the medical technology sector, focusing on developing and commercialising synthetic wound care solutions. Its flagship NovoSorb platform uses a biodegradable polymer technology designed to support tissue regeneration and wound management.

The company’s key products include NovoSorb BTM (Biodegradable Temporising Matrix) and NovoSorb MTX. These products are used in complex wound applications, including major burns, trauma and reconstructive procedures.

Investors generally assess medical technology companies through factors including product adoption, regulatory approvals, clinical evidence, manufacturing capability, reimbursement conditions and commercial expansion.

Polynovo’s Business model is focused on expanding product utilisation across healthcare systems while increasing sales through direct commercial channels, particularly in the United States.

The wound care market is influenced by factors including ageing populations, healthcare expenditure, surgical procedures and Demand for advanced treatment options.

FY26 trading update and investor focus

Polynovo’s FY26 trading update highlighted preliminary unaudited financial performance for the year ended 30 June 2026. The company reported group revenue of AUD 150.0 million, up 16.1% compared with AUD 129.2 million in FY25. On a constant currency basis, revenue increased 20.3%.

Group commercial sales increased to AUD 138.4 million, up 16.7% compared with AUD 118.6 million in FY25. United States commercial sales reached AUD 102.1 million, up 15.6%, while Rest of World commercial sales increased to AUD 36.3 million, up 20.0%.

NovoSorb BTM commercial sales increased to AUD 125.8 million from AUD 111.9 million, while NovoSorb MTX sales increased to AUD 12.6 million from AUD 6.7 million, representing growth of 89.6%.

Polynovo reported cash and cash equivalents of AUD 35.4 million at 30 June 2026, compared with AUD 33.5 million at 30 June 2025. Operating Cash Flow increased to AUD 24.0 million from AUD 3.1 million, while free cash flow improved to AUD 10.4 million from an outflow of AUD 10.1 million in FY25.

The company completed construction of its new manufacturing facility, with validation activities progressing. Capital Expenditure requirements were largely complete, with approximately AUD 1.5 million remaining for additional machinery expected during H1 FY27.

Polynovo also highlighted continued expansion of its US commercial infrastructure, with its frontline sales organisation exceeding 100 personnel. The company stated that NovoSorb SynPath was planned for commercial launch during FY27.

The company noted that audited FY26 financial results, including final EBITDA and NPAT outcomes, were scheduled for release after completion of year-end financial procedures.

Investors continue to monitor US sales growth, reimbursement changes, manufacturing scale-up and future product launches.

Factors investors generally monitor

Polynovo’s performance is influenced by product adoption, healthcare provider acceptance, reimbursement conditions, manufacturing capacity and regulatory developments.

Commercial sales growth is a key metric because medical technology companies rely on increasing product usage across healthcare systems. Investors generally monitor sales by region, customer adoption and expansion into new wound care applications.

The US market remains an important focus area due to its size and contribution to revenue. Changes in reimbursement policies, hospital purchasing behaviour and competitive dynamics can influence future growth.

Manufacturing capability is another important consideration. Expanding production capacity can support increased demand, but investors monitor execution, validation processes and capital requirements.

Clinical evidence also plays an important role. Healthcare providers often assess advanced wound care products based on clinical outcomes, published evidence and practical benefits.

New product development remains a focus area. The planned launch of NovoSorb SynPath represents an additional opportunity, although adoption and commercial execution remain important factors.

Understanding the share price movement

Polynovo’s 6.73% share price increase on 20 August 2026 may reflect changes in investor sentiment, trading activity or positioning within the healthcare sector. However, daily share price movements alone do not necessarily represent changes in the company’s underlying fundamentals.

Healthcare technology stocks can experience short-term Volatility as investors reassess sales growth, product launches, regulatory developments and future Earnings potential.

For Polynovo, investors are likely to continue monitoring US commercial performance, reimbursement conditions, manufacturing expansion and progress across its wound care product portfolio.

Conclusion

Polynovo (ASX:PNV) closed at AUD 1.11, up 6.73% on 20 August 2026. The company continues to develop and commercialise advanced wound care products through its NovoSorb technology platform.

While the daily share price movement reflects market activity, investors generally assess Polynovo through broader factors including revenue growth, commercial adoption, manufacturing capability, reimbursement conditions and product expansion. The FY26 trading update highlighted higher revenue, improved cash flow generation and continued progress in expanding the company’s global wound care platform.

FAQs

Q: What was Polynovo’s share price movement on 20 August 2026?

A: Polynovo (ASX:PNV) closed at AUD 1.11, up 6.73% on 20 August 2026.

Q: What does Polynovo do?

A: Polynovo develops advanced wound care products using its NovoSorb biodegradable polymer technology.

Q: What were Polynovo’s FY26 revenue highlights?

A: Polynovo reported FY26 revenue of AUD 150.0 million, group commercial sales of AUD 138.4 million and US commercial sales of AUD 102.1 million.

Q: What is NovoSorb BTM?

A: NovoSorb BTM is Polynovo’s synthetic wound care product designed for complex wound management applications.

Q: What factors influence Polynovo’s outlook?

A: Investors generally monitor product adoption, US sales growth, reimbursement conditions, manufacturing capacity, regulatory progress and new product launches.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.